Ascorbic acid use in hyporesponders to Epoetin alfa

Area of Science:

• Nephrology
• Hematology
• Nutritional Science

Background:

• Hemodialysis (HD) patients often exhibit hyporesponsiveness to Epoetin alfa.
• Intravenous (IV) ascorbic acid has been explored to mobilize ferritin stores and improve Epoetin alfa response.
• Ascorbic acid's role in hemosiderin metabolism and iron overload in HD patients is under investigation.

Purpose of the Study:

• To evaluate the potential of IV ascorbic acid as an adjuvant therapy for Epoetin alfa hyporesponsiveness in HD patients.
• To explore the mechanisms by which ascorbic acid might influence iron stores and Epoetin alfa efficacy.
• To assess the safety and efficacy of IV ascorbic acid in iron-overloaded HD patients.

Main Methods:

• Review of existing clinical studies and literature on IV ascorbic acid in HD patients.
• Analysis of potential mechanisms involving ferritin and hemosiderin mobilization.
• Examination of reported dosages, durations, and observed effects of IV ascorbic acid therapy.

Main Results:

• IV ascorbic acid shows potential in mobilizing ferritin stores in some hyporesponsive HD patients.
• The precise prediction of patient response and the role of hemosiderin remain unclear.
• Short-term studies (up to 12 weeks) with specific dosages (300-500 mg TIW) have not shown significant adverse effects.

Conclusions:

• IV ascorbic acid may be considered as an adjuvant therapy for "iron-overloaded" and Epoetin alfa hyporesponsive HD patients.
• Long-term safety, particularly the risk of secondary oxalosis, requires monitoring and further investigation.
• Large-scale, prospective, controlled trials are necessary to establish definitive long-term safety and efficacy.